Abingworth enters another VIPE with Epigenomics fundraising
This article was originally published in Scrip
Executive Summary
Abingworth, the life sciences-focused venture capital firm, has made its third VIPE (venture investment in public equity) deal in just over a year.It has participatedin a rights offering from Epigenomics which made it the German diagnostics firm's largest shareholder.